Get started
Author

Miguel Borregón

Observed names: M. Borregón, Miguel Borregon Rivilla, Miguel Borregon-Rivilla, Miguel Borregón Rivilla, Miguel Borregón-Rivilla
Observed institutions: Hospital General Universitario Morales Meseguer, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Hospital Virgen de la Salud, Hospital General Universitario de Elche, Hospital Universitario de Fuenlabrada, Hospital Marina Baixa
ORCID: 0000-0002-3699-1171
Observed ORCID: 0000-0002-3699-1171
OpenAlex ID: A5078289875
Anti-drug antibodies in the current management of cancer
2022 · Miguel Borregón, Katherine Martínez, et al. · Cancer Chemotherapy and Pharmacology · 19
Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis
2025 · Javier David Benitez Fuentes, Jorge Bartolome Arcilla, et al. · Frontiers in Oncology · 10
Potential Negative Impacts of the CCI4EU Initiative on Spain
2024 · Javier David Benitez Fuentes, Asia Ferrandez Arias, et al. · JCO Global Oncology · 7
PDF
Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study
2024 · Pilar García-Alfonso, Paula Jimenez-Fonseca, et al. · The Oncologist · 4
Screening and treatment of latent tuberculosis in patients with solid tumors and systemic cancer therapy
2024 · Miguel Borregón, David Sánchez, et al. · Clinical & Translational Oncology · 4
A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study
2025 · Sonia Servitja, Maria Castro-Henriques, et al. · Clinical & Translational Oncology · 3
PDF
Revisiting Alma Ata: A Blueprint for Cancer Care
2025 · Javier-David Benitez-Fuentes, Rodrigo Lastra del Prado, et al. · Cancer Control · 3
Cancer-associated thoracic aorta arterial thrombosis: case report and review of the literature
2025 · Miguel Borregón, María Valero, et al. · Frontiers in Cardiovascular Medicine · 3
Addressing Tumor Board Bad Habits and Risks: A Call for Rational Resource Management
2025 · Miguel Borregón, María Torrente, et al. · JCO Oncology Practice · 2
P3.18.12 ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study - Trial in Progress
2025 · M. Provencio, D. Aguiar, et al. · Journal of Thoracic Oncology · 1
Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping–Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report
2025 · David Sánchez García, Beatriz Grau Mirete, et al. · Case Reports in Oncological Medicine · 1
PDF
Pileflebitis mesentérica secundaria a infección por coronavirus
2021 · Manuel Alejandro Mazariegos-Rubi, Miguel Borregón-Rivilla, et al. · Atención Primaria Práctica · 1
PDF
ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance, a narrative review
2026 · Miguel Borregón, María-Asunción Algarra, et al. · Molecular Biology Reports
Baseline Gustave Roussy Immune Score and Survival in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemoimmunotherapy
2026 · David Sánchez-García, Miguel Borregón-Rivilla, et al. · Cancer Management and Research
PDF
Pneumocystis jirovecii pneumonia and prophylaxis in patients with solid tumours: a narrative review
2026 · Miguel Borregón, María-Asunción Algarra, et al. · Clinical & Translational Oncology
Correction: A topical nociceutical formulation ameliorates chemotherapy‑induced peripheral neuropathy: a pilot randomized clinical study
2025 · Sonia Servitja, Maria Castro-Henriques, et al. · Clinical & Translational Oncology
PDF
Reply to: From Discussion to Direction: Tumor Boards Need Clinical Editorial Leadership
2025 · Miguel Borregón Rivilla, María Torrente, et al. · JCO Oncology Practice
Abstract P1-02-07: Topical modulation of nociceptor epidermal terminals delays and ameliorates CIPN improving the quality of life of breast cancer patients
2025 · Sonia Servitja, Maria Castro-Henriques, et al. · Clinical Cancer Research
Previous history of solid tumor in patients presenting tuberculosis: a multicenter retrospective study in a low-tuberculosis-incidence area
2025 · Miguel Borregón, Paula Rodríguez, et al. · Clinical & Translational Oncology
Reply to: Correction Regarding Commentary “Comprehensive Cancer Infrastructures for the European Union—Coordination and Support Action—CCI4EU CSA”
2025 · Javier David Benitez Fuentes, Asia Ferrández-Arias, et al. · JCO Global Oncology
Acute urinary retention and delirium in end-of-life cancer patients.
2024 · Miguel Borregón, Javier-David Benítez-Fuentes, et al. · Research Square
Works count: 21
Citation count: 58
H-index: 4
I10-index: 2
Year
Topic
Type